

Biomax News • Biomax News • Biomax News •

FOR IMMEDIATE RELEASE

Contact:

Peyton Hughes
Biomax Informatics AG
Lochhamer Str. 11
D-82152 Martinsried
Germany
Tel: +49 89 895574-0
Fax: +49 89 895574-825
Internet site: www.biomax.de

**BIOMAX INFORMATICS AG
Licenses the BioRS™ Integration and Retrieval Plus System to
MILLENNIUM PHARMACEUTICALS, Inc.**

MARTINSRIED, Germany — July 9, 2001 — Biomax Informatics AG announced today that Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) has licensed the BioRS™ Integration and Retrieval Plus System (version 4.0). Millennium will use the system, which is known for its high-speed data retrieval and user-friendly administrative functions, as a bioinformatics tool in their highly regarded technology platform.

“Millennium’s unique approach to drug discovery and development is at the forefront of the industry,” said Tim Clark, vice president, informatics at Millennium. “As a result, we are continuously evaluating software and technology products, and services that will help us enhance our productivity. We performed an extensive analysis of the BioRS system over several months and it proved to be a stable, comprehensive and efficient system. The speed and agility with which we assess drug targets in our gene-to-patient platform requires a system that can handle a broad spectrum of user scenarios for large data volumes. The BioRS system has the potential to meet our aggressive needs.”

“The Millennium bioinformatics group is one of the most highly-qualified teams we have ever worked with. We are pleased that after giving BioRS the most demanding and unrelenting evaluation it has ever endured, the Biomax system was identified as the ideal choice,” said Dr. Klaus Heumann, CEO of Biomax Informatics.

In addition to working with flat-file databases, the BioRS Plus system offers the ability to integrate and work with relational databases. This user-friendly design is recognized as a very attractive feature for administrators. It also facilitates an

efficient development of configurations for various research groups without the need to devote unnecessary time to learn how to operate the system.

About the BioRS Integration and Retrieval System

The BioRS system, first launched in 1998, is a high-speed, sophisticated search and retrieval system for biological information, such as DNA sequences. The speed and flexibility of the BioRS system greatly facilitates gene discovery projects, including genomics, proteomics and drug targeting and delivery. The system enables researchers to quickly and efficiently retrieve all known biological data on a given topic, independent of the size of the database or the complexity of the query. The BioRS system uses convenient web interfaces and standardizes data formats from different databases using Extensible Markup Language (XML) for quick, easy access to data, independent of the source format. Both flat-file and relational databases, including proprietary databases, are easily integrated.

Recently, Biomax released a new BioRS version, 4.0, which further facilitates the use of relational databases. With this new version, the format of an existing relational database can be copied making the creation and integration of new relational databases as easy as possible. Additionally, the new release allows users to execute searches using phrases with all indexed fields, refining queries for more relevant search results.

Also, the query archive has been enhanced so that queries created by an individual user may be accessed by others. This new feature allows information to be shared more efficiently by reducing redundant searches and ensuring that research goals are reached even more quickly.

In January 2001, Biomax granted InforMax of Rockville, Maryland, exclusive, worldwide distribution rights to the BioRS Integration and Retrieval System.

About Biomax

Biomax Informatics AG (Martinsried, Germany), a leader in the development of customized bioinformatics solutions, was founded in 1997 as a spin-off of the GSF-MIPS academic research group, now the German Research Center for Environment and Health-Institute for Bioinformatics (GSF-IBI). Founded by Dr. D. Frishman, Dr. K. Heumann and Prof. Dr. H. W. Mewes, Biomax developed the well-known Pedant-Pro™ Sequence Analysis Suite, the HarvESTer EST Assembly and Clustering System, and other bioinformatics tools used in metabolic pathway, proteomics, and gene expression analyses. Additional information about Biomax can be found at the company's site on the World Wide Web at www.biomax.de.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products, with a goal of delivering personalized medicine.



Through the industrialization of this gene-to-patient platform, Millennium is also striving to accelerate the process of drug discovery and development. Headquartered in Cambridge, MA., Millennium currently employs more than 1,400 people.

This press release contains “forward-looking statements,” including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various risks may cause Millennium’s actual results to differ materially, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Biomax, BioRS, and Pedant-Pro are registered trademarks of Biomax Informatics AG in Germany and other countries.

Registered names, trademarks, etc., used in this document, even when not specifically marked as such, are not to be considered unprotected by law. All other products or company names are used for identification purposes only, and may be the trademarks of their respective owners.

###

